

Ingrid E Lundberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5300321/publications.pdf>

Version: 2024-02-01

215
papers

11,611
citations

25034

57
h-index

36028

97
g-index

227
all docs

227
docs citations

227
times ranked

7915
citing authors

#	ARTICLE	IF	CITATIONS
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1955-1964.	0.9	754
2	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017, 69, 2271-2282.	5.6	391
3	Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. <i>Arthritis and Rheumatism</i> , 2005, 52, 1824-1835.	6.7	308
4	Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. <i>Journal of Physiology</i> , 2000, 529, 243-262.	2.9	285
5	Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 1997, 40, 865-874.	6.7	246
6	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , 2021, 7, 86.	30.5	212
7	Classification of myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 269-278.	8.0	210
8	Autoantibodies to cytosolic 5â€²-â€³nucleotidase 1A in inclusion body myositis. <i>Annals of Neurology</i> , 2013, 73, 397-407.	5.3	206
9	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.9	183
10	Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. <i>Journal of Neuroimmunology</i> , 1995, 63, 9-16.	2.3	181
11	Pathogenesis, classification and treatment of inflammatory myopathies. <i>Nature Reviews Rheumatology</i> , 2011, 7, 297-306.	8.0	178
12	Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology. <i>Arthritis and Rheumatism</i> , 2008, 59, 677-685.	6.7	164
13	A possible mechanism for endogenous activation of the type I interferon system in myositis patients with antiâ€³Joâ€³-1 or antiâ€³Ro 52/antiâ€³Ro 60 autoantibodies. <i>Arthritis and Rheumatism</i> , 2007, 56, 3112-3124.	6.7	154
14	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14â€³16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.6	148
15	Interstitial lung disease in polymyositis and dermatomyositis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 701-706.	4.3	128
16	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.9	127
17	Skeletal Muscle Fibers Express Major Histocompatibility Complex Class II Antigens Independently of Inflammatory Infiltrates in Inflammatory Myopathies. <i>American Journal of Pathology</i> , 2001, 159, 1263-1273.	3.8	121
18	Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. <i>Arthritis and Rheumatism</i> , 2007, 57, 768-777.	6.7	121

#	ARTICLE	IF	CITATIONS
19	Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. <i>Rheumatology</i> , 2010, 49, 2370-2374.	1.9	121
20	Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16955-16960.	7.1	120
21	Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2007, 57, 694-702.	6.7	116
22	Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.9	116
23	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017, 3, e000507.	3.8	115
24	Decreased expression of interleukin-1Î±, interleukin-1Î², and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. <i>Arthritis and Rheumatism</i> , 2000, 43, 336.	6.7	112
25	SPORADIC INCLUSION BODY MYOSITIS: PILOT STUDY ON THE EFFECTS OF A HOME EXERCISE PROGRAM ON MUSCLE FUNCTION, HISTOPATHOLOGY AND INFLAMMATORY REACTION. <i>Journal of Rehabilitation Medicine</i> , 2003, 35, 31-35.	1.1	105
26	Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. <i>Arthritis and Rheumatism</i> , 2004, 50, 1586-1594.	6.7	102
27	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 55-62.	0.9	100
28	Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. <i>Current Opinion in Rheumatology</i> , 2010, 22, 633-638.	4.3	99
29	Anti-PL-7 (Anti-Threonyl-tRNA Synthetase) Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2012, 91, 206-211.	1.0	98
30	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 792-801.	0.9	92
31	Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. <i>Autoimmunity Reviews</i> , 2009, 9, 58-61.	5.8	89
32	Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies. <i>RMD Open</i> , 2016, 2, e000291.	3.8	89
33	Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 40-47.	0.9	89
34	The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. <i>Current Rheumatology Reports</i> , 2000, 2, 216-224.	4.7	87
35	Interleukin-1? expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: Important pathogenic features independent of inflammatory cell clusters in muscle tissue. <i>Arthritis and Rheumatism</i> , 2002, 46, 1044-1055.	6.7	86
36	Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12â€¦months follow-up. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 913-920.	0.9	83

#	ARTICLE	IF	CITATIONS
37	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.9	81
38	Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. <i>Arthritis Research and Therapy</i> , 2013, 15, R83.	3.5	80
39	Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. <i>Rheumatology</i> , 2014, 53, 397-405.	1.9	76
40	The skeletal muscle arachidonic acid cascade in health and inflammatory disease. <i>Nature Reviews Rheumatology</i> , 2014, 10, 295-303.	8.0	75
41	A Longitudinal, Integrated, Clinical, Histological and mRNA Profiling Study of Resistance Exercise in Myositis. <i>Molecular Medicine</i> , 2010, 16, 455-464.	4.4	74
42	Resistive Home Exercise in Patients with Recent-onset Polymyositis and Dermatomyositis – A Randomized Controlled Single-blinded Study with a 2-year Followup. <i>Journal of Rheumatology</i> , 2014, 41, 1124-1132.	2.0	74
43	Expanded T cell receptor V β 2-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28 ^{null} T cells. <i>Arthritis and Rheumatism</i> , 2010, 62, 3457-3466.	6.7	71
44	Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. <i>Arthritis and Rheumatism</i> , 2007, 57, 1303-1310.	6.7	70
45	Endothelial cell activation and neovascularization are prominent in dermatomyositis. <i>Journal of Autoimmune Diseases</i> , 2006, 3, 2.	1.0	69
46	Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. <i>Arthritis and Rheumatism</i> , 2006, 55, 114-122.	6.7	67
47	Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. <i>Rheumatology</i> , 2017, 56, 802-810.	1.9	66
48	New Myositis Classification Criteria – What We Have Learned Since Bohan and Peter. <i>Current Rheumatology Reports</i> , 2018, 20, 18.	4.7	65
49	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. <i>JCI Insight</i> , 2020, 5, .	5.0	65
50	Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. <i>Arthritis and Rheumatism</i> , 1999, 42, 1649-1654.	6.7	64
51	Cytokines in idiopathic inflammatory myopathies. <i>Autoimmunity</i> , 2006, 39, 177-190.	2.6	63
52	Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1738-1750.	5.6	62
53	Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 858-860.	0.9	61
54	Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2012, 24, 201-207.	4.3	59

#	ARTICLE	IF	CITATIONS
55	High-intensity resistance training in multiple sclerosis – An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition. <i>Journal of the Neurological Sciences</i> , 2016, 362, 251-257.	0.6	59
56	Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2007, 56, 674-687.	6.7	58
57	Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2007, 9, 208.	3.5	57
58	Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. <i>Current Opinion in Rheumatology</i> , 2009, 21, 599-603.	4.3	56
59	Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 204-210.	0.9	56
60	Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3224-3238.	6.7	55
61	Molecular effects of exercise in patients with inflammatory rheumatic disease. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 597-604.	3.2	55
62	Experiencing virtual patients in clinical learning: a phenomenological study. <i>Advances in Health Sciences Education</i> , 2011, 16, 331-345.	3.3	54
63	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	5.6	52
64	The Prognosis of Mixed Connective Tissue Disease. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 535-547.	1.9	51
65	Idiopathic inflammatory myositis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 149-168.	3.3	50
66	Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case-control study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1803-1808.	0.9	49
67	The role of exercise in the rehabilitation of idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2005, 17, 164-171.	4.3	48
68	Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. <i>Rheumatology</i> , 2011, 50, 578-585.	1.9	46
69	Preclinical target validation using patient-derived cells. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 149-150.	46.4	46
70	Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3280-3289.	6.7	45
71	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 67-75.	2.6	44
72	Limited effects of high-dose intravenous immunoglobulin (IVIg) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1276-1283.	0.9	43

#	ARTICLE	IF	CITATIONS
73	Response to: "Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice"™ by Hořvar et al. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e91-e91.	0.9	43
74	Polymyositis and Dermatomyositis: Pathophysiology. <i>Rheumatic Disease Clinics of North America</i> , 2011, 37, 159-171.	1.9	41
75	Immune Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	5.6	41
76	Idiopathic Inflammatory Myopathies. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 569-581.	1.9	41
77	Nitrosative modifications of the Ca ²⁺ release complex and actin underlie arthritis-induced muscle weakness. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1907-1914.	0.9	40
78	Therapy of myositis. <i>Current Opinion in Rheumatology</i> , 2014, 26, 704-711.	4.3	39
79	Development of the myositis activities profile–validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. <i>Journal of Rheumatology</i> , 2002, 29, 2386-92.	2.0	39
80	Possible pathogenic mechanisms in inflammatory myopathies. <i>Rheumatic Disease Clinics of North America</i> , 2002, 28, 799-822.	1.9	38
81	Traditional Cardiovascular Risk Factors and Coronary Artery Calcification in Adults With Polymyositis and Dermatomyositis: A Danish Multicenter Study. <i>Arthritis Care and Research</i> , 2015, 67, 848-854.	3.4	38
82	CD4+ and CD8+ CD28 ^{null} T Cells Are Cytotoxic to Autologous Muscle Cells in Patients With Polymyositis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2016-2026.	5.6	38
83	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 133-139.	1.1	37
84	Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. <i>Arthritis and Rheumatism</i> , 2007, 56, 372-383.	6.7	37
85	Patients with regular physical activity before onset of rheumatoid arthritis present with milder disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1541-1544.	0.9	37
86	New Insights into the Benefits of Exercise for Muscle Health in Patients with Idiopathic Inflammatory Myositis. <i>Current Rheumatology Reports</i> , 2014, 16, 429.	4.7	36
87	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 241-250.	0.9	36
88	Current Treatment for Myositis. <i>Current Treatment Options in Rheumatology</i> , 2018, 4, 299-315.	1.4	36
89	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects. <i>Rheumatology</i> , 2017, 56, 1884-1893.	1.9	33
90	Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. <i>Journal of Clinical Investigation</i> , 2015, 125, 4612-4624.	8.2	33

#	ARTICLE	IF	CITATIONS
91	An outsourced health-enhancing physical activity programme for people with rheumatoid arthritis: exploration of adherence and response. <i>Rheumatology</i> , 2015, 54, 1065-1073.	1.9	32
92	Physiological evidence for diversification of IFN γ - and IFN β -mediated response programs in different autoimmune diseases. <i>Arthritis Research and Therapy</i> , 2016, 18, 49.	3.5	32
93	Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis. <i>Arthritis Research and Therapy</i> , 2016, 18, 80.	3.5	31
94	Corticosteroidsâ€”from an idea to clinical use. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 7-19.	3.3	30
95	Sera from antiâ€”Joâ€”1â€”positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. <i>Arthritis and Rheumatism</i> , 2009, 60, 2524-2530.	6.7	30
96	Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor β expression in muscle tissue of patients with polymyositis or dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1055-1063.	0.9	30
97	Proinflammatory Histidylâ€”Transfer β -RNA Synthetaseâ€”Specific CD $^{+}$ T Cells in the Blood and Lungs of Patients With Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2020, 72, 179-191.	5.6	30
98	Patient-reported Outcomes and Adult Patientsâ€™ Disease Experience in the Idiopathic Inflammatory Myopathies. Report from the OMERACT 11 Myositis Special Interest Group. <i>Journal of Rheumatology</i> , 2014, 41, 581-592.	2.0	28
99	Women in academic rheumatology. <i>Arthritis and Rheumatism</i> , 2005, 52, 697-706.	6.7	27
100	The type I interferon system in idiopathic inflammatory myopathies. <i>Autoimmunity</i> , 2010, 43, 239-243.	2.6	27
101	Pregnancy Outcome in Idiopathic Inflammatory Myopathy Patients in a Multicenter Study. <i>Journal of Rheumatology</i> , 2014, 41, 2492.2-2494.	2.0	27
102	An update on polymyalgia rheumatica. <i>Journal of Internal Medicine</i> , 2022, 292, 717-732.	6.0	27
103	Patientsâ€™ Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure â€” Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2492-2495.	2.0	26
104	Educational needs of health professionals working in rheumatology in Europe. <i>RMD Open</i> , 2016, 2, e000337.	3.8	26
105	Effect of endurance exercise on microRNAs in myositis skeletal muscleâ€”A randomized controlled study. <i>PLoS ONE</i> , 2017, 12, e0183292.	2.5	26
106	Long-term, health-enhancing physical activity is associated with reduction of pain but not pain sensitivity or improved exercise-induced hypoalgesia in persons with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 262.	3.5	26
107	Autoantibody targets in vaccine-associated narcolepsy. <i>Autoimmunity</i> , 2016, 49, 421-433.	2.6	25
108	The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. <i>Journal of Autoimmunity</i> , 2017, 78, 46-56.	6.5	25

#	ARTICLE	IF	CITATIONS
109	Pain sensitivity at rest and during muscle contraction in persons with rheumatoid arthritis: a substudy within the Physical Activity in Rheumatoid Arthritis 2010 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 48.	3.5	25
110	Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. <i>Journal of Rheumatology</i> , 2019, 46, 106-111.	2.0	25
111	Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis. <i>Journal of Pathology</i> , 2019, 249, 215-226.	4.5	24
112	Developments in the scientific and clinical understanding of inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2008, 10, 220.	3.5	23
113	Higher pain sensitivity and lower muscle strength in postmenopausal women with early rheumatoid arthritis compared with age-matched healthy women – a pilot study. <i>Disability and Rehabilitation</i> , 2013, 35, 1350-1356.	1.8	23
114	Intravenous immune globulin suppresses angiogenesis in mice and humans. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	17.1	23
115	Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study. <i>Journal of Rheumatology</i> , 2018, 45, 538-546.	2.0	23
116	Impaired left atrial dynamics and its improvement by guided physical activity reveal left atrial strain as a novel early indicator of reversible cardiac dysfunction in rheumatoid arthritis. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1106-1108.	1.8	23
117	Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1 positive polymyositis and dermatomyositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 158.	3.5	23
118	OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2019, 46, 1351-1354.	2.0	23
119	Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. <i>Clinical Rheumatology</i> , 2016, 35, 2363-2367.	2.2	22
120	Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis. <i>Arthritis Research and Therapy</i> , 2018, 20, 83.	3.5	22
121	Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. <i>Rheumatology</i> , 2019, 58, 1214-1220.	1.9	22
122	Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis. <i>Rheumatology</i> , 2016, 55, 1987-1992.	1.9	21
123	Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study. <i>Journal of Rheumatology</i> , 2017, 44, 1683-1687.	2.0	21
124	T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients. <i>Arthritis Research and Therapy</i> , 2018, 20, 188.	3.5	21
125	Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1463-1475.	10.5	21
126	Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. <i>Muscle and Nerve</i> , 2009, 39, 674-682.	2.2	20

#	ARTICLE	IF	CITATIONS
127	Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents. <i>Arthritis Research and Therapy</i> , 2016, 18, 136.	3.5	20
128	Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 293-299.	0.9	19
129	Rheumatology training experience across Europe: analysis of core competences. <i>Arthritis Research and Therapy</i> , 2016, 18, 213.	3.5	19
130	Response to: '2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e78-e78.	0.9	19
131	Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: A nationwide study 2002-2016. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 331-337.	3.4	19
132	Cardiac abnormalities assessed by non-invasive techniques in patients with newly diagnosed idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 706-14.	0.8	19
133	Registries in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2013, 25, 729-734.	4.3	18
134	Differences and similarities in rheumatology specialty training programmes across European countries. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1183-1187.	0.9	18
135	Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 492-497.	3.4	18
136	Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 176-177.	0.8	18
137	Complement <i>C4</i> Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2022, 74, 1440-1450.	5.6	17
138	Pathogenesis of idiopathic inflammatory myopathies. <i>Current Rheumatology Reports</i> , 2006, 8, 188-195.	4.7	16
139	Association of Anti-Transcription Intermediary Factor 1 ³ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis. <i>Arthritis Care and Research</i> , 2018, 70, 648-651.	3.4	16
140	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. <i>Rheumatology</i> , 2020, 59, 1026-1030.	1.9	16
141	Vascular involvement in the pathogenesis of idiopathic inflammatory myopathies. <i>Autoimmunity</i> , 2009, 42, 615-626.	2.6	15
142	Successful Lung Transplantation in a Case of Rapidly Progressive Interstitial Lung Disease Associated with Antimelanoma Differentiation-associated Gene 5 Antibodies. <i>Journal of Rheumatology</i> , 2018, 45, 581-583.	2.0	15
143	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. <i>Arthritis and Rheumatology</i> , 2014, 66, S70-S71.	5.6	14
144	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. <i>RMD Open</i> , 2016, 2, e000240.	3.8	14

#	ARTICLE	IF	CITATIONS
145	Venous Thromboembolic Events in Idiopathic Inflammatory Myopathy: Occurrence and Relation to Disease Onset. <i>Arthritis Care and Research</i> , 2018, 70, 1849-1855.	3.4	14
146	Myositis an evolving spectrum of disease. <i>Immunological Medicine</i> , 2018, 41, 46-54.	2.6	14
147	Concurrent positive anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase antibody with reducing body myopathy: Possible double trouble. <i>Neuromuscular Disorders</i> , 2019, 29, 543-548.	0.6	14
148	Inflammatory muscle disease: Clinical presentation and assessment of patients. <i>Current Rheumatology Reports</i> , 2007, 9, 273-279.	4.7	13
149	Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. <i>Rheumatology</i> , 2018, 57, 2149-2157.	1.9	13
150	Acute Coronary Syndrome in Idiopathic Inflammatory Myopathies: A Population-based Study. <i>Journal of Rheumatology</i> , 2019, 46, 1509-1514.	2.0	13
151	Polymyositis: does it really exist as a distinct clinical subset?. <i>Current Opinion in Rheumatology</i> , 2021, 33, 537-543.	4.3	13
152	Technology Insight: tools for research, diagnosis and clinical assessment of treatment in idiopathic inflammatory myopathies. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 282-290.	3.2	12
153	Inflammatory Diseases of Muscle and Other Myopathies. , 2017, , 1461-1488.e5.		12
154	Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies. <i>Scientific Reports</i> , 2018, 8, 17958.	3.3	12
155	Pregnancy outcomes in women with idiopathic inflammatory myopathy, before and after diagnosisâ€”a population-based study. <i>Rheumatology</i> , 2020, 59, 2572-2580.	1.9	12
156	Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE. <i>Arthritis Research and Therapy</i> , 2021, 23, 132.	3.5	12
157	Work ability in patients with polymyositis and dermatomyositis: An explorative and descriptive study. <i>Work</i> , 2016, 53, 265-277.	1.1	11
158	An Outsourced Health-enhancing Physical Activity Program for People with Rheumatoid Arthritis: Study of the Maintenance Phase. <i>Journal of Rheumatology</i> , 2018, 45, 1093-1100.	2.0	11
159	The Risk of Ischemic and Hemorrhagic Stroke in Patients With Idiopathic Inflammatory Myopathies: A Swedish Populationâ€Based Cohort Study. <i>Arthritis Care and Research</i> , 2019, 71, 970-976.	3.4	11
160	Treatment-resistant inflammatory myopathy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 427-440.	3.3	10
161	Inflammatory lung disease a potential risk factor for onset of idiopathic inflammatory myopathies: results from a pilot study. <i>RMD Open</i> , 2016, 2, e000342.	3.8	9
162	Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, annrheumdis-2021-219914.	0.9	9

#	ARTICLE	IF	CITATIONS
163	New tools for diagnosis and therapy. <i>Nature Reviews Rheumatology</i> , 2017, 13, 74-76.	8.0	8
164	Effect of CTLA4â€¦g (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12732.	2.7	8
165	Increasing Reasoning Awareness: Video Analysis of Studentsâ€™ Two-Party Virtual Patient Interactions. <i>JMIR Medical Education</i> , 2018, 4, e4.	2.6	8
166	Clinical phenotype, autoantibody profile and HLA-DR-type in Vietnamese patients with idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2019, 58, 361-363.	1.9	7
167	Contribution of Rare Genetic Variation to Disease Susceptibility in a Large Scandinavian Myositis Cohort. <i>Arthritis and Rheumatology</i> , 2022, 74, 342-352.	5.6	7
168	Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome. <i>Arthritis Research and Therapy</i> , 2022, 24, 62.	3.5	7
169	Cardiovascular Autonomic Function Changes and Predictors During a 2-Year Physical Activity Program in Rheumatoid Arthritis: A PARA 2010 Substudy. <i>Frontiers in Medicine</i> , 2021, 8, 788243.	2.6	7
170	Response to: â€˜Semi-quantitative analysis of line blot assay for myositis-specific and myositis-associated antibodies: a better performance?â€™ by Cavazzana <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e153-e153.	0.9	6
171	Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 943-948.	3.4	6
172	Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 983-988.	3.4	6
173	Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort. <i>Rheumatology</i> , 2022, 61, 4145-4154.	1.9	6
174	Use of biologic agents in idiopathic inflammatory myopathies in Sweden: a descriptive study of real life treatment. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 512-515.	0.8	6
175	Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 67-73.	0.8	6
176	International collaboration including patients is essential to develop new therapies for patients with myositis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 234-240.	4.3	5
177	Expert Perspective: Management of Refractory Inflammatory Myopathy. <i>Arthritis and Rheumatology</i> , 2021, 73, 1394-1407.	5.6	5
178	Antiâ€¦Jo1 autoantibodies, from clinic to the bench. <i>Rheumatology & Autoimmunity</i> , 2022, 2, 57-68.	0.8	5
179	ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis. <i>Rheumatology</i> , 2022, 61, 4991-4996.	1.9	5
180	Autoantibodies: Pathogenic or epiphenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, , 101767.	3.3	5

#	ARTICLE	IF	CITATIONS
181	Response to: "Comment on: "Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria" by Greco et al" by Knitza et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e86-e86.	0.9	4
182	Myositis-specific autoantibodies and QTc changes by ECG in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2022, 61, 4076-4086.	1.9	4
183	Response to: "Detection of myositis-specific antibodies" by Vulsteke et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e8-e8.	0.9	3
184	Response to: "Detection of myositis-specific antibodies: additional notes" by Infantino et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e30-e30.	0.9	3
185	Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry-Based Study. <i>Arthritis Care and Research</i> , 2022, 74, 468-477.	3.4	3
186	Pulmonary involvement in polymyositis and dermatomyositis. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 45-56.	0.3	2
187	CD28 ⁺ T cells from myositis patients are cytotoxic to autologous muscle cells in vitro. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A44.2-A45.	0.9	2
188	No Signs of Inflammation during Knee Surgery with Ischemia: A Study Involving Inhaled Nitric Oxide. <i>Mediators of Inflammation</i> , 2014, 2014, 1-8.	3.0	2
189	Response to: "Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria" by Cavagna et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrhumdis-2017-212382.	0.9	2
190	Clinical characteristics of Vietnamese patients with idiopathic inflammatory myopathies and autoantibodies to aminoacyl-tRNA synthetases. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 663-670.	1.9	2
191	Anti-Inflammatory Properties of Chemical Probes in Human Whole Blood: Focus on Prostaglandin E2 Production. <i>Frontiers in Pharmacology</i> , 2020, 11, 613.	3.5	2
192	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 976-976.	5.6	1
193	Response to: "Time to personalise the treatment of anti-MDA-5 associated lung disease" by Lake et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e53-e53.	0.9	1
194	Response to: "Comment on: standardisation of myositis-specific antibodies: where are we today?" by Infantino et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e116-e116.	0.9	1
195	Evaluation of a New Skeletal Troponin I Assay in Patients with Idiopathic Inflammatory Myopathies. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 320-331.	1.3	1
196	Reproductive Pattern in Women with Idiopathic Inflammatory Myopathy: A Population-based Study. <i>Journal of Rheumatology</i> , 2020, 47, 1392-1396.	2.0	1
197	Identifying novel B-cell targets for chronic inflammatory autoimmune disease by screening of chemical probes in a patient-derived cell assay. <i>Translational Research</i> , 2021, 229, 69-82.	5.0	1
198	Response to: "Correspondence on "EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups" by Lrfan et al." <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e41-e41.	0.9	1

#	ARTICLE	IF	CITATIONS
199	Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 583-587.	2.0	1
200	Features of repeated muscle biopsies and phenotypes of monocytes in paired blood samples and clinical long-term response to treatment in patients with idiopathic inflammatory myopathy: a pilot study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 42-49.	0.8	1
201	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 309-319.	0.8	1
202	Atherosclerosis in Vietnamese patients with systemic sclerosis and its relation to disease and traditional risk factors. <i>Rheumatology Advances in Practice</i> , 0, , .	0.7	1
203	Crosstalk between nitrosative stress and altered Ca ²⁺ handling in arthritis-induced skeletal muscle dysfunction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A43.3-A44.	0.9	0
204	IFN signature is associated with autoantibody profiles in patients with myositis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A49.1-A49.	0.9	0
205	A5.27â€¦Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A40.2-A40.	0.9	0
206	A3.11â€¦Immunosuppressive Effects of Glucocorticoids and Regulatory T Cells on CD28null T Cells in Vitro. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A17.1-A17.	0.9	0
207	175â€¦Myositis-Specific Autoantibodies Rarely Coexist with Each Other: An Analysis of the Ukyonet and Eumyonet Cohorts. <i>Rheumatology</i> , 0, , .	1.9	0
208	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 243-244.	5.6	0
209	02.48â€¦Inhibition of in vitro b cell maturation and igg secretion by new chemical probes in assays using blood cells from patients with sle and iim. , 2017, , .		0
210	08.10â€¦Serum lipid and fatty acid profiles are altered in patients with polymyositis or dermatomyositis. , 2017, , .		0
211	SAT0290â€¦TRADITIONAL AND DISEASE-RELATED RISK FACTORS FOR ARTERIAL AND VENOUS THROMBOTIC EVENTS (TE) IN IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM). , 2019, , .		0
212	AB0652â€¦QTC INTERVAL PROLONGATION IN A SCANDINAVIAN COHORT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES AND SYSTEMIC SCLEROSIS: CORRELATIONS WITH CLINICAL VARIABLES. , 2019, , .		0
213	THU0331â€¦SKELETAL TROPONIN I A POSSIBLE NOVEL BIOMARKER FOR MANAGEMENT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
214	O32â€¦Skin proteome investigation in cutaneous lupus erythematosus (CLE) reveals novel unique disease pathways. , 2020, , .		0
215	P222â€¦Clinical features of extra-muscular disease in dermatomyositis and anti-synthetase syndrome patients with skin involvement classified by presence of disease-specific autoantibodies: results from the EuroMyositis registry. <i>Rheumatology</i> , 2022, 61, .	1.9	0